Cornercap Investment Counsel Inc. Has $225,000 Stake in Solventum Co. (NYSE:SOLV)

Cornercap Investment Counsel Inc. lowered its stake in shares of Solventum Co. (NYSE:SOLV) by 27.5% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 3,227 shares of the company’s stock after selling 1,227 shares during the period. Cornercap Investment Counsel Inc.’s holdings in Solventum were worth $225,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Mitsubishi UFJ Trust & Banking Corp acquired a new position in shares of Solventum in the first quarter valued at $5,747,000. GABELLI & Co INVESTMENT ADVISERS INC. acquired a new position in shares of Solventum in the 1st quarter valued at $209,000. LRI Investments LLC bought a new position in shares of Solventum during the 1st quarter worth about $43,000. Magnetar Financial LLC bought a new stake in Solventum in the first quarter valued at about $3,478,000. Finally, Alpine Global Management LLC acquired a new position in Solventum in the first quarter worth about $1,766,000.

Solventum Stock Down 0.5 %

Solventum stock opened at $67.12 on Tuesday. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. The business has a 50-day moving average of $70.54 and a 200-day moving average of $62.20. Solventum Co. has a 1 year low of $47.16 and a 1 year high of $96.05.

Analysts Set New Price Targets

Several analysts recently commented on the company. BTIG Research began coverage on Solventum in a research note on Thursday, September 5th. They issued a “neutral” rating on the stock. Morgan Stanley raised their price target on Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a report on Monday, November 11th. Wells Fargo & Company cut their price objective on Solventum from $69.00 to $64.00 and set an “equal weight” rating for the company in a research report on Friday, August 9th. Stifel Nicolaus started coverage on Solventum in a report on Tuesday, October 8th. They set a “buy” rating and a $82.00 target price on the stock. Finally, Wolfe Research started coverage on Solventum in a report on Thursday, September 26th. They set a “peer perform” rating for the company. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, Solventum presently has a consensus rating of “Hold” and a consensus target price of $68.00.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.